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Background. With significant reductions in the rate of HIV mother-to-child transmission (MTCT) in South Africa, each case of failed prevention 
of MTCT (PMTCT) should be investigated. 
Objective. To establish the cause(s) of MTCT at Khayelitsha’s Community Health Centre (CHC) in order to identify obstacles to MTCT elimination.
Methods. Routinely collected data were reviewed for all HIV-infected infants identified at Khayelitsha Site B CHC from January 2012 to April 2013.
Results. A total of 926/1 158 (80%) of exposed infants had polymerase chain reaction (PCR) results, with 15/926 (1.6%) PCR-positive. Median 
(interquartile range (IQR)) values for the maternal indicators were as follows: maternal age, 27 (23 - 31) years; parity, 2 (1 - 3); gestational age at 
antenatal presentation, 21.5 (17.5 - 30.5) weeks; CD4+, 377 (219 - 446) cells/µl. Of the 15 PCR-positive infants, five received ART, five received 
AZT and five received no prophylaxis. Viral loads were not monitored for any of the women receiving antenatal ART. Nine of the 15 (60%) 
delivered in hospital, with 6/9 requiring caesarean section. The median (IQR) infant birth weight was 3.0 (2.6 - 3.5) kg. All received prophylactic 
nevirapine post exposure. Two of the 15 were clinically unwell at birth, and 14 (86.7%) were breastfed, with 10 (66.7%) recorded as exclusively 
breastfed. Median (IQR) time between delivery and PCR results was 6.6 (6.1 - 7.3) weeks. 
Discussion. PMTCT programmes must consider each PCR-positive infant as a sentinel event that can provide valuable insight into correcting 
ongoing clinical and programmatic reasons for HIV transmission. The main risk factors for MTCT identified in this study were late presentation 
for antenatal care, inadequate antenatal PMTCT prophylaxis and a lack of viral load monitoring. 
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Over the last decade, South 
Africa (SA) has experienced 
dramatic improvements in its 
prevention of mother-to- child-
transmission (PMTCT) pro-
gramme. The first national-level PMTCT pro-
gramme was introduced in 2002 and included 
single-dose nevirapine (Sd-NVP) during labour 
for the mother and to the baby postpartum, 
modified obstetric practices, infant feeding 
counselling, and the provision of free infant 
formula to HIV-positive mothers who chose 
not to breastfeed. [1] In 2005, pregnant women 
with CD4+ counts ≤200 cells/µl were eligible for 
triple-drug antiretroviral (ARV) therapy (ART) 
for their own health, and in 2008 pregnant 
women with CD4+ counts >200 cells/µl were 
offered ‘dual therapy’ (azidothymidine (AZT) 
from 28 weeks, and Sd-NVP in labour) and Sd-
NVP with AZT postnatal infant prophylaxis. In 
2010, there were further improvements to the 
PMTCT programme. These included routine 
HIV testing and counselling for pregnant 
women, dual therapy to prevent MTCT of HIV, 
highly active ARV therapy for pregnant women 
with a CD4+ cell count ≤350 cells/µl, postnatal 
infant prophylaxis with NVP for breastfeeding 
HIV-positive women and intensified efforts to 
integrate PMTCT services into routine maternal 
and child health (MCH) services.[2] The success 
of the national PMTCT programme was seen 
in the 2010 SA PMTCT evaluation (the first 
national evaluation of the PMTCT programme 
in SA), which demonstrated a significant 
reduction in MTCT to 3.5% (compared with 
an estimated transmission risk of 20 - 30% 
without any intervention).[3] The SA PMTCT 
evaluation study also showed high uptake of 
PMTCT services nationally, with more than 
98% of women getting an HIV test during 
pregnancy and 92% of HIV-infected mothers 
receiving ARV treatment or prophylaxis.[3] 
SA’s latest and arguably most controversial 
PMTCT improvements came in April 2013: 
SA followed the World Health Organization 
recommendations by offering ART to all HIV-
positive pregnant or breastfeeding women 
regardless of CD4+ count.[4] In light of such 
achievements, what more is needed to ‘close 
the gaps’ in the PMTCT cascade and reach the 
Millennium Development Goal of elimination 
of MTCT by 2015? 
The objective of this review was to establish 
possible cause(s) of transmission for HIV-
infected infants in order to identify ongoing 
obstacles to elimination of MTCT. Antenatal 
and PMTCT history, delivery information and 
feeding options were obtained from routinely 
collected data held in antenatal clinic registers 
and clinical files. 
Methods
For this case series, Médecins Sans Frontières 
(MSF) partnered with the Western Cape 
Department of Health (WC DoH) to review 
and document case histories of all PCR-positive 
infants found in the HIV-exposed infant register 
at Khayelitsha’s Site B Community Health 
Centre in Cape Town from 1 January 2012 to 
30 April 2013. Khayelitsha’s Site B Community 
Health Centre is a campus that provides 
primary healthcare services including casualty, 
outpatient department for adults and children, 
an HIV/tuberculosis (TB)/drug-resistant TB 
(DR-TB) clinic, and a midwifery and obstetrics 
unit. Within its paediatric services, it has a 
baby clinic that is dedicated to the registration 
and care of HIV-exposed infants. It is the 
responsibility of this baby clinic to ensure that 
all HIV-exposed infants who attend receive a 
PCR test at around 6 weeks postpartum. 
Results
A total of 1 158 HIV-exposed infants were 
recorded in the exposed infant register at 
Khayelitsha Site B Community Health Centre 
over the 16-month study period (from 1 January 
2012 to 30 April 2013). Of these, 926 (80%) of 
exposed infants had HIV DNA PCR results 
available, and 15 (1.6%) were PCR-positive. 
Review of the maternal histories for the 
15 positive infants (Table 1) found that the 
median (interquartile range (IQR)) maternal 
age was 27 (23 - 31) years, median parity 
was 2 (1 - 3), and median gestational age at 
antenatal presentation was 21.5 (17.5 - 30.5) 
weeks. Baseline CD4+ count was <350 cells/ µl 
in 46.7% of women, with a median (IQR) 
CD4+ count of 377 (219 - 446) cells/µl. One-
third of these mothers received ART: two 
started ART after 33 weeks’ gestation and 
received no more than 5 weeks of ART prior 
to delivery, one started ART at 17 weeks’ 
gestation but then defaulted treatment at 
month 1 on ART, and the remaining two 
started ART at 25 and 21 weeks’ gestation, 
respectively, but had clinic ally unwell 
babies at birth, suggesting early in utero 
transmission. Five mothers received AZT 
for a median duration of 20 weeks (based on 
clinical records only; no record of degree of 
adherence to AZT dual therapy was found) 
and an additional five received no PMTCT 
prophylaxis (two defaulted on ART prior to 
Table 1. Clinical and demographic features of mother-infant pairs 
where transmission of HIV occurred
Patient characteristics (N=15)
Maternal age (years), median (IQR) 27 (23 - 31)
Parity, median (IQR) 2 (1 - 3)
Gestation at 1st ANC presentation (weeks), median (IQR) 21.5 (17.5 - 30.5)
Maternal CD4+ count (cells/µl), median (IQR) 377 (219 - 446)
CD4+ count (cells/µl),  n (%)
<200 3 (20.0)
200 - 349 4 (26.7)
≥350 8 (53.3)
PMTCT prophylaxis provided, n (%) 
ART 5 (33.3)
AZT 5 (33.3)
No prophylaxis 5 (33.3)
Mothers requiring hospital care at delivery, n (%) 9 (60)
Infant birth weight (kg), median (IQR) 3.0 (2.6 - 3.5)
Infants clinically unwell at birth, n (%) 2 (13.3)
Breastfed infants, n (%)
Documented breastfeeding of any duration 14 (86.7)
Documented exclusive breastfeeding 10 (66.7)
Duration between delivery and PCR test (weeks), median (IQR) 6.6 (6.1 - 7.3)
IQR = interquartile range; ANC = antenatal clinic; PMTCT = prevention of mother-to-child transmission; 
ART = antiretroviral therapy; AZT = azidothymidine; PCR = polymerase chain reaction.
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onset of pregnancy but verbally reported being on ART at booking, 
one presented in labour, one tested negative in pregnancy then 
positive in labour, and one did not receive prophylaxis despite 
booking at 6 weeks’ gestation). Viral loads were not monitored for 
women on antenatal ART, as the national ART/PMTCT guidelines 
at the time required 1st viral load to be drawn at month 4 on ART 
and not prior. Out of 15 mothers, 9 (60%) required hospital care at 
delivery, with 6 requiring caesarean section.
Review of the early infant histories for the 15 positive infants revealed 
the following: median (IQR) infant birth weight was 3.0 (2.6 - 3.5) kg; 
all received nevirapine as postexposure prophylaxis (the duration and 
adherence to which was unclear from clinic records); and 14 (87%) 
were breastfed with 10 (67%) recorded as ‘exclusively breastfed’. Median 
(IQR) time between delivery and PCR results was 6.6 (6.1 - 7.3) weeks.
Discussion
This case series points to several critical gaps in the PMTCT 
cascade in this setting. It was of great concern to discover that, 
consistently over the 16-month period, only 80% of exposed infants 
had documented PCR results. This finding is of particular concern 
when considered in the context of the SA PMTCT evaluation 
study reported intention to obtain infant PCR testing at 6 weeks; 
the study found that only 35% of HIV-positive mothers indicated 
that they planned to obtain early infant diagnosis for their infant 
during their 6-week immunisation visit. Multiple possible causes 
were identified for the suboptimal PCR testing rate, including poor 
patient education of the need to return at around 6 weeks for a PCR 
test, poor staff knowledge (because of staff turnover and shortages) 
of the need to ensure a PCR is done in infants presenting between 
6 weeks and 18 months, the fragmentation of child health services 
within the facility, and insufficient staff motivation to follow up on 
missing PCR results or infants not returning for their initial PCR test. 
Further research is required to analyse in more detail all the causes 
of inadequate infant PCR testing coverage, along with intensified 
effort to improve the postnatal linkage to care of all HIV-exposed 
infants and their mothers. 
Analysis of the maternal antenatal histories for infants found to be 
HIV-infected revealed further gaps in the PMTCT cascade. The need 
to intensify community awareness of the importance of early antenatal 
booking was highlighted in the following findings: median (IQR) 
gestational age at antenatal presentation was 21.5 (17.5 - 30.5) weeks, 
and one mother presented for the first time in labour (no antenatal 
care) despite this being her 3rd pregnancy and already knowing her 
HIV status. To address this gap, MSF and WC DoH have partnered with 
the Treatment Action Campaign to launch a community awareness 
campaign that aims to improve patient literacy particularly on the issue 
of early antenatal booking. 
Inconsistency in the provision of antenatal prophylaxis and a 
lack of viral load monitoring for pregnant or breastfeeding women 
on ART were identified as further significant gaps. From clinical 
records, the median duration of AZT dual therapy was 20 weeks, 
but was complicated by: poor maternal understanding of the 
importance of adherence to AZT twice daily; pregnant women often 
running out of their AZT between appointments; staff not routinely 
checking AZT pill counts during antenatal visits; and no system for 
monitoring AZT provision or adherence. One mother, whose child 
is now HIV-infected, was not provided antenatal AZT prophylaxis 
despite booking at 6 weeks’ gestation and presenting a further four 
times in her pregnancy; this woman was told she had booked too 
early to start prophylaxis on her first visit, and antenatal staff failed 
to detect that she had not been issued AZT on each subsequent 
visit. The absence of routine viral load monitoring for women on 
ART at antenatal booking and subsequently through pregnancy 
and breastfeeding resulted in failing to detect women who had 
defaulted ART prior to or during pregnancy; two mothers of HIV-
infected infants in our review defaulted on ART prior to onset of 
pregnancy but verbally reported being on ART at their antenatal 
booking. Vigilance in viral load monitoring for women on ART 
during pregnancy is essential, and infant feeding choice should take 
into account a woman’s actual or likely viral load at delivery. Of the 
15 HIV-infected infants, 14 were breastfed, with 10 documented as 
being exclusively breastfed. In these cases, HIV transmission may 
have occurred due to breastfeeding in the presence of a high viral 
load. In a small number of cases, a complicated delivery was also 
linked with transmission.
These data come from a case series, and as such, have fundamental 
limitations related to absence of a comparator group of HIV-exposed 
but uninfected infants. Nonetheless, several key concerns emerge 
clearly. The main risk factors for MTCT identified in our review of 
the case histories of PCR-positive infants were late presentation to 
antenatal care, inadequate provision or duration of antenatal PMTCT 
prophylaxis, and a lack of viral load monitoring to determine whether 
a pregnant woman is virologically suppressed at delivery and during 
breastfeeding. Women with any of these risk factors should be urgently 
identified as high risk for transmission and provided additional 
adherence support, home visits by community care workers, an early 
infant PCR test, tailored infant feeding advice and dual postnatal infant 
prophylaxis. 
Recent policy developments calling for provision of ART for all HIV-
positive pregnant or breastfeeding women regardless of CD4+ count 
is welcomed, and will undoubtedly improve PMTCT outcomes in SA. 
However, the elimination of MTCT will require intensified efforts to 
strengthen each step in the PMTCT cascade, from promotion of early 
antenatal booking to timely identification and appropriate management 
of high-risk pregnant or breastfeeding women. The introduction of 
routine birth PCR testing for high-risk infants would allow for early 
detection of infants infected with HIV; this would reduce the risk that 
HIV-positive infants are lost to follow-up prior to diagnosis and allow 
rapid initiation of ART. PMTCT programmes must consider each 
PCR-positive infant as a sentinel event that can provide valuable insight 
into correcting ongoing clinical and programmatic reasons for HIV 
transmission.
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